/

ALKS

Alkermes plcPre-market

40.26−0.35 −0.86%USD

NasdaqGS · as of Oct 12, 16:00 ET · 15m delay

Open

40.67

Prev close

40.61

Day range

40.0040.87

52-week range

27.0055.67

Volume

2.24M1.20×

Mkt cap

6.75B

P/E ttm

105.95

Fwd P/E

22.26

EPS ttm

0.3800

Div yield

0.00%

Earnings

Jul 28, 2026

From 52w high

−27.68%

Price Chart

Yahoo Finance · delayed

ALKSOct 12, 2026O 40.67H 40.87L 40.00C 40.26−0.35 (−0.86%)Vol 2.24M

SMA 5045.82
SMA 20039.48

1Y change +29.00% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ALKS Alkermes plc · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −5.85%
1 month: −12.42%
3 months: −22.38%
6 months: +19.29%
Year to date: +43.89%
1 year: +29.00%

Valuation & ownership

Market cap: 6.75B
Enterprise value: 7.67B
P/E (ttm): 105.95
Forward P/E: 22.26
PEG ratio: 1.96
Price / book: 3.73
Price / sales (ttm): 4.05
EV / EBITDA: 26.92
EPS (ttm): 0.3800
EPS (forward): 1.81
Beta (5y monthly): 0.27
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 167.76M
Float: 155.19M
Short % of float: 14.72%
Short ratio (days): 8.24
Held by insiders: 1.40%
Held by institutions: 107.47%
Avg volume (3m): 1.87M
50-day average: 45.82
200-day average: 39.48
52-week change: +29.00%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 35.1
vs 50-day SMA: −12.13%
vs 200-day SMA: +1.98%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 3.51%
Realised vol (20d, ann.): 38.9%
From 52-week high: −27.68%
From 52-week low: +49.11%

ANR

Analyst Consensus

18 analysts

Consensus

Buy

1.74 on a 1 (strong buy) – 5 (sell) scale

Mean target

56.28

+39.79% implied

Low 38.00Median 58.00High 83.00

Recommendation trend

Now14 / 4 / 1
1m ago

DES

About Alkermes plc

Yahoo Finance profile

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 2,050
Headquarters: Dublin, Ireland
Website: alkermes.com
Officers: Mr. Blair C. Jackson President, CEO & Director

SEAS

Seasonality · ALKS

2007–2026 · monthly returns

Strongest month Dec +5.81%Weakest month Oct −2.37%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	21.1	-11.2	17.5	-4.7	25.2	24.2	-6.5	-4.1	-13.8	-0.6			+43.9%
2025	9.6	8.9	-3.8	-12.9	6.4	-6.5	-7.4	9.4	3.6	2.3	-3.6	-5.4	−2.7%
2024	-2.5	9.8	-8.8	-9.3	-4.6	3.0	13.4	4.1	-1.6	-8.2	12.9	-0.9	+3.7%
2023	9.6	-6.6	5.4	1.3	1.3	8.2	-6.5	-0.3	-4.0	-13.6	-0.2	14.9	+6.2%
2022	9.6	-2.5	5.8	9.7	3.5	-0.2	-14.1	-7.5	-5.7	1.7	9.2	5.4	+12.3%
2021	5.2	-9.3	-1.9	17.8	3.0	8.2	5.5	20.8	-1.3	-1.8	-27.6	6.1	+16.6%
2020	-14.7	19.7	-30.8	-4.9	19.3	18.6	-7.2	-8.2	0.2	-1.9	12.4	9.3	−2.2%
2019	11.4	1.2	9.7	-16.9	-29.0	4.6	2.8	-9.4	-7.0	0.1	7.6	-2.9	−30.9%
2018	4.5	-0.2	1.5	-23.6	6.6	-12.8	6.5	2.3	-5.4	-3.8	-10.8	-19.0	−46.1%
2017	-2.6	4.4	3.5	-0.4	-0.8	0.4	-6.1	-6.7	0.1	-4.1	7.2	4.7	−1.5%
2016	-59.7	0.8	5.9	16.3	16.8	-6.9	15.5	-12.3	7.4	7.2	12.7	-2.2	−30.0%
2015	23.4	-2.8	-13.2	-9.2	10.3	5.3	8.8	-14.9	-1.5	22.6	2.0	8.2	+35.6%
2014	19.7	-0.0	-9.4	4.9	-1.0	9.9	-15.0	4.6	-4.2	17.9	8.8	6.4	+44.0%
2013	24.5	-5.8	9.1	29.2	2.1	-8.2	17.1	-5.4	5.9	4.7	14.7	0.7	+119.5%
2012	8.4	-6.1	5.0	-6.7	-9.7	8.6	9.5	-1.3	13.1	-10.7	4.3	-4.1	+6.7%
2011	5.1	11.0	-9.6	11.4	27.0	1.5	-7.3	0.6	-12.1	14.7	-12.6	13.5	+41.4%
2010	16.3	4.8	13.2	1.1	-13.3	9.6	3.6	2.9	10.4	-21.0	-9.4	17.2	+30.5%
2009	7.7	-12.1	20.3	-36.9	6.1	33.3	-4.6	-12.3	1.5	-13.3	12.7	4.8	−11.6%
2008	-14.6	-2.9	-8.2	4.6	1.9	-2.4	27.4	-15.1	-0.5	-25.7	-25.3	44.3	−31.7%
2007	11.6	9.9	-5.9	6.4	-2.3	-9.1	-2.5	18.3	9.2	-12.0	-12.0	9.3	+16.6%

INSD

Insider Activity · ALKS

Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

144.7K shares

Sells, 6 months

125.4K shares

Net shares

+19.3K

Net change in insider shares

+0.80%

Date	Insider	Transaction	Shares	Value
Sep 2, 2026	Gaffin David JosephOfficer	Sale at price 48.01 per share.	2K	$97.65K
Aug 31, 2026	Hopkinson Craig COfficer	Conversion of Exercise of derivative security at price 24.59 per share.	5K	$122.95K
Aug 31, 2026	Hopkinson Craig COfficer	Sale at price 46.99 per share.	9K	$422.87K
Aug 16, 2026	Nichols Christian ToddOfficer	Sale at price 49.19 - 49.65 per share.	7.6K	$372.94K
Aug 2, 2026	Hopkinson Craig COfficer	Conversion of Exercise of derivative security at price 19.34 - 24.59 per share.	5K	$122.40K
Aug 2, 2026	Snyderman Nancy LynnDirector	Conversion of Exercise of derivative security at price 46.72 per share.	44.5K	$2.08M
Aug 2, 2026	Gaffin David JosephOfficer	Sale at price 48.58 per share.	2K	$98.81K
Aug 2, 2026	Snyderman Nancy LynnDirector	Sale at price 50.35 per share.	44.5K	$2.24M
Aug 2, 2026	Hopkinson Craig COfficer	Sale at price 48.58 per share.	9K	$437.22K
Jul 5, 2026	Gaffin David JosephOfficer	Sale at price 54.03 per share.	2K	$109.90K
Jun 30, 2026	Hopkinson Craig COfficer	Conversion of Exercise of derivative security at price 19.34 per share.	5K	$96.70K
Jun 30, 2026	Hopkinson Craig COfficer	Sale at price 51.46 - 52.13 per share.	9K	$463.62K
Jun 11, 2026	Wright Christopher IDirector	Sale at price 45.10 per share.	2K	$90.20K
Jun 3, 2026	Gaffin David JosephOfficer	Sale at price 43.05 per share.	2K	$87.56K
May 31, 2026	Hopkinson Craig COfficer	Conversion of Exercise of derivative security at price 19.34 per share.	5K	$96.70K
May 31, 2026	Hopkinson Craig COfficer	Sale at price 41.67 per share.	9K	$375.04K
May 28, 2026	Parisi Samuel JosephOfficer	Conversion of Exercise of derivative security at price 19.34 - 20.03 per share.	16.2K	$315.98K
May 28, 2026	Parisi Samuel JosephOfficer	Sale at price 42.36 per share.	16.2K	$687.01K
May 20, 2026	Gaynor Richard Brian M.D.Director	—	6.1K	—
May 20, 2026	Wright Christopher IDirector	—	6.1K	—

CONG

Congress Trades · ALKS

House reports since 2025

Members

1 last bought

Buys

~$32.5K

Sells

~$0

Net

+$32.5K

est. bought − sold

Latest

Jul 30, 26

Gilbert Cisneros

Members who traded it

Member	Buys	Sells	Est. net	Last move
Gilbert Cisneros CA31	1		+$32.5K	Bought Jul 30, 26

Bought and sold by quarter (est.)

House members' ALKS trades, newest first
Traded	Member	Owner	Type	Amount	Filed	Report
Jul 30, 26	Gilbert Cisneros CA31	Self	Buy	$15,001 - $50,000	Sep 4, 26 (36d)	PDF

From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades

ALKS

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ALKS

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Alkermes plc

Seasonality · ALKS

Insider Activity · ALKS

Congress Trades · ALKS

Members who traded it

Bought and sold by quarter (est.)

Congress Trades · ALKS

Members who traded it

Bought and sold by quarter (est.)

Insider Activity · ALKS

Seasonality · ALKS

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Alkermes plc

Financial Snapshot

Earnings & Dividends

News